PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell Podcast
10 November 2023 - 12:00AM
IBN, a leading communications organization focused on linking
public companies to the investment community, has unveiled the
latest episode of The Bell2Bell Podcast, featuring an exclusive
interview with David Hough, Chief Medical Officer at PaxMedica.
In this engaging episode, David Hough shared key updates
following PaxMedica's recent meeting with the FDA, highlighting
pivotal achievements such as:
- FDA discussion of PaxMedica's data from the PAX-HAT 301 Study
and comprehensive nonclinical programs.
- PAX-HAT-301 study confirmed as positive evidence for African
Sleeping Sickness treatment, expected to result in substantial time
and resource savings for PaxMedica.
- FDA acknowledgment of PaxMedica's comprehensive nonclinical
program, including safety pharmacology, ADME, and toxicology
studies.
- Waivers granted for the thorough QT/QTc studies, affirming data
relevance to the patient population.
- 2024 NDA submission anticipation underscores PaxMedica's
commitment to neglected tropical disease treatments.
For the full episode, please visit:
https://podcast.bell2bell.com/
Join the esteemed host, Bell2Bell's Stuart Smith, and David
Hough, the Chief Medical Officer of PaxMedica, Inc. (Nasdaq: PXMD),
to gain deeper insights into the company's recent FDA meeting.
To listen to the episode, visit:
https://podcast.bell2bell.com.
The latest installment of The Bell2Bell
Podcast continues to reinforce IBN’s commitment to the
expansion of its robust network of brands, client partners,
followers, and the growing IBN Podcast Series. For more than
17 years, IBN has leveraged this commitment to provide unparalleled
distribution and corporate messaging solutions to 500+ public
and private companies.
To learn more about IBN’s achievements and milestones via a
visual timeline, visit: https://IBN.fm/TimeLine
About PaxMedica Inc.
PaxMedica, Inc. is a forward-looking clinical-stage
biopharmaceutical firm specializing in cutting-edge anti-purinergic
drug therapies (APT) aimed at addressing a range of challenging
neurologic disorders, including Autism Spectrum Disorder (ASD) and
Human African Trypanosomiasis (HAT). Our portfolio encompasses
critical areas within the neurology field, with a focus on
pioneering advancements in both ASD and HAT treatments. We are
dedicated to the continuous development and evaluation of our
pioneering program, PAX-101-an intravenous suramin formulation that
lies at the heart of our efforts, particularly focused on
innovative ASD and HAT treatment solutions. Our ongoing research
initiatives not only prioritize the needs of ASD and HAT patients
but also extend to exploring potential therapeutic applications for
related conditions. To learn more about our transformative work,
please visit www.paxmedica.com.
Interested investors and shareholders are encouraged to sign up
for press releases and industry updates by registering for Email
Alerts at https://www.paxmedica.com/email-alerts and by
following PaxMedica on Twitter and LinkedIn.
About IBN
IBN consists of financial brands introduced to the
investment public over the course of 17+ years. With IBN, we have
amassed a collective audience of millions of social media
followers. These distinctive investor brands aim to fulfill the
unique needs of a growing base of client-partners. IBN will
continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized
teams of experts to serve our increasingly diversified list of
clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides:
(1) access to a network of wire solutions
via InvestorWire to reach all target markets, industries
and demographics in the most effective manner possible; (2) article
and editorial syndication to 5,000+ news outlets;
(3) Press Release Enhancement to ensure maximum impact;
(4) full-scale distribution to a growing social
media audience; (5) a full array of corporate
communications solutions; and (6) total news coverage
solutions.
For more information, please
visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or
re-published: http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBNLos Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From May 2024 to Jun 2024
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From Jun 2023 to Jun 2024